Skip to main content

Clinical Trials Using Pembrolizumab

Review the clinical trials studying pembrolizumab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 351-375 of 432

Pembrolizumab and M032 (NSC 733972) in Treating Patients with Newly Diagnosed or Recurrent/Progressive Glioblastoma, Anaplastic Astrocytoma, or Gliosarcoma
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Enfortumab Vedotin and Pembrolizumab Plus Radiation Therapy for the Treatment of Muscle Invasive Bladder Cancer, EV-PRIME Trial
Status: Active
Location: University of California San Francisco, San Francisco, California
External Beam Radiation Therapy and Brachytherapy with Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer
Status: Active
Location: 5 locations
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Status: Active
Location: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Personalized Neoantigen Peptide-Based Vaccine in Combination with Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Status: Active
Location: 6 locations
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Status: Active
Location: USC / Norris Comprehensive Cancer Center, Los Angeles, California
Split Course Adaptive Radiation Therapy and Immunotherapy with or without Chemotherapy for the Treatment of Stage IV or Locally Advanced Lung Cancer, SiCARIO Study
Status: Active
Location: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
Pembrolizumab in Treating Participants with Unresectable Thymoma or Thymic Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
First In Human Study of CX-801 in Advanced Solid Tumors
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
Status: Active
Location: 2 locations
Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors
Status: Active
Location: Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas
Pembrolizumab with or without Metformin in Treating Patients with Stage III-IV Melanoma
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
A Study of ZN-c3 in Participants With Solid Tumors
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination with Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer
Status: Active
Location: University of California Davis Comprehensive Cancer Center, Sacramento, California
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Alpelisib and Pembrolizumab for the Treatment of Patients with Locally Advanced, Unresectable, or Metastatic Melanoma or Triple Negative Breast Cancer, SELENA Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)
Status: Active
Location: UC San Diego Moores Cancer Center, La Jolla, California
Palbociclib with Pembrolizumab for the Treatment of Patients with Locally Advanced, Metastatic or Unresectable Sarcomas
Status: Active
Location: University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa
RNA-Lipid Particle Vaccine for the Treatment of Early Melanoma Recurrence after Anti-PD-1 Antibody Therapy or Uresectable or Metastatic Soft Tissue Sarcoma
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida
Study of INCB081776 with Radiation Therapy and Other Treatments for Head and Neck Cancer
Status: Active
Location: University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin